Chapter 17: The Immune Response

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Guive.

Today we have, well, it's a big one.

A really big one.

We're taking on the vertebrate immune response, using Chapter 17 of Carp and Molecular Biology as our only guide.

And our mission is to really break down the system piece by piece.

It's probably the most complex system in the body.

So before we get into any specific diseases, let's just define our terms.

What are we actually talking about when we say immunity?

In vertebrates, it's really the combined activity of two things.

You have these dispersed individual cells, and then you have specific centralized lymphoid organs.

Okay, so that's the bone marrow, the spleen, the lymph nodes.

And the thymus, which is crucial.

And in fact, the bone marrow and the thymus are what we call the central immune system.

And why central?

Because that's where the key fighting cells, the lymphocytes, actually differentiate and mature.

That's their training ground.

And their job description.

What's the ultimate goal of this whole system?

At its core, it's a high -speed molecular screening process.

It has to constantly recognize macromolecules that are foreign or non -self.

And then, and this is the key part, only then mount a very specific attack.

So the entire challenge is telling friend from foe.

Instantly.

Everywhere in the body.

Exactly.

And the weapons it uses are incredibly diverse.

You have killer cells, cells that literally ingest and devour invaders.

And then you have the soluble proteins, which are like chemical artillery.

They can neutralize toxins, immobilize pathogens, or plump them together, a process called agglutination.

Or just kill them outright.

Or just kill them outright.

But this complexity means we're in a constant evolutionary arms race.

We see that playing out with diseases like AIDS, tuberculosis, malaria pathogens that are always one step ahead.

Right.

But there's an even more dangerous scenario, and that's an inappropriate response.

When the system turns its weapons on the host, well, that's where you get autoimmune disease.

A topic we're going to get into in a lot of detail later.

So with that landscape, let's Let's start with a catastrophic failure.

The chapter opens with the 2014 Ebola crisis.

It's a terrifying example.

A virus with a fatality rate often at or above 50 percent.

And it achieves that because it's a master of evasion.

And it's so insidious because its main targets are the very cells meant to defend us.

Right.

It binds to receptors on white blood cells and hijacks their internal machinery.

It turns our own defenses into viral factories.

And because those white blood cells are moving through the lymphatic system, the virus spreads systemically, almost immediately.

One of its most effective strategies is this multi -pronged attack on our earliest warning signals.

Specifically, it circumvents interferons.

And interferons are a huge deal for the innate immune system.

They're absolutely critical.

They're signaling proteins that normally trigger widespread antiviral activity.

They slow down protein translation.

They destroy viral RNA and they induce apoptosis or programmed cell death in infected cells.

And Ebola just stops all of that cold.

It does.

And the result is devastating.

You get this whole cell death of host cells, which leads to lymphopenia, a dangerously low count of white blood cells.

The book describes this pseudo -colored electron micrograph.

And it really brings it home.

It shows these numerous little Ebola particles, colored blue, just budding from a single infected cell that's colored yellow.

The cell is literally bursting with the enemy.

And then in the late stages, as tissue damage gets really severe, the body can launch this final uncontrolled assault.

The cytokine storm.

The cytokine storm.

It's a sudden massive release of pro -inflammatory signals.

And instead of helping, this massive inflammation is thought to be a major contributor to lethality.

So the immune system, in its desperation, actually becomes the primary cause of death.

It's a tragic over -escalation.

And even though we now have effective Ebola vaccines, researchers are still intensely focused on understanding these bypass mechanisms.

This brings us to the foundational concept in the chapter.

The two general categories of response.

Right.

You have the innate response, which is immediate and non -specific.

It doesn't care what the invader is, just that it's foreign.

And then the adaptive or acquired response.

This one is slower, but it's highly specific.

And crucially, it establishes memory.

We also categorize the threats themselves.

Intracellular pathogens, like viruses, which hide inside our cells.

And then extracellular pathogens, which includes most bacteria that are just floating around outside of cells.

And figure 17 .2 in the book does a great job of laying this all out.

On the left, you have the innate mechanisms.

This is phagocytosis, which is just engulfing the invader.

Right.

Then there's bacterial killing by complement proteins, ipoptosis of compromised cells by natural killer cells, or NK cells.

And finally, that viral resistance that's induced by interferon alpha signaling.

Then on the right side of the diagram, you have the adaptive tools.

This is the specialized stuff.

Like antibodies neutralizing toxins.

Or a process called opsonization.

This is where antibodies code a pathogen, kind of like putting handles on it, flagging it for destruction.

And finally, apoptosis of infected cells, but this time induced by activated T cells.

A much more specific killing.

But the most important part of that diagram is the green arrow connecting the two sides.

The bridge.

The bridge.

Innate immune cells, like dendritic cells and macrophages, don't just kill.

They act as intelligence agents.

They ingest foreign proteins, process them, and then use those fragments to stimulate only the specific adaptive cells needed for that particular threat.

So they connect the immediate general defense to the slow, sophisticated, tailored response.

Exactly.

All right, so let's start with that immediate action.

The innate immune responses.

This is the first line of defense.

It's instantaneous.

It doesn't require any prior contact with the pathogen.

The first contact is usually with those sentinels, the phagocytic cells.

Macrophages and dendritic cells.

Primarily.

And this is where we hit a really brilliant conceptual leap in immunology, which was proposed by Charles Janeway Jr.

back in 1989.

He suggested that these innate cells use general microbial sensors.

He called them pattern recognition receptors, or PRRs.

Right, and they're not looking for unique signatures of one specific bacterium.

They're looking for what he called PAMPs, pathogen -associated molecular patterns.

And that distinction is everything.

PAMPs are macromolecules that are absolutely essential for the pathogen's life, but they're completely absent in our own host cells.

The cell isn't trying to read the invader's name tag.

It's just identifying universal parts of the enemy that only enemies have.

And the story of how we discovered these sensors is, well, it's pretty surprising.

It involves fruit flies.

Drosophila melanogaster.

In 1996, Jules Hoffman's lab found a mutant fly that was just incredibly susceptible to fungal infections.

And the description of figure 17 .3 really makes it clear.

It shows a dead mutant fly that's just covered in germinating fungal hyphae.

It's a devastating image.

And this total lack of defense was all due to the absence of a single functional protein called toll.

And toll was already known to do something else in the fly.

It was.

It controlled embryonic polarity.

So it had this dual function development and innate immunity.

But the huge clue was that it acted through the NF -kappa -B pathway.

A pathway that was already known to be involved in immune activation invertebrates.

That was the smoking gun.

Janeway and Ruslan Medzitov used that clue to clone the human versions, which led to the discovery of the toll -like receptors, or TLRs.

Then Bruce Buehler provided the definitive proof, showing that one of them, TLR4, was the specific receptor for lipopolysaccharide, or LPS.

Which is the signature component of Gram -negative bacteria.

We now know humans have at least 10 functional TLRs.

And their placement is strategic.

Some are on the cell surface to catch extracellular microbes.

And others are inside, within andosomal and lysosomal membranes, to detect microbes that have already been brought into the cell.

And the PMPs they recognize are so diverse.

Things like LPS, peptidoglycan, flagellin from bacteria.

All the way to double -stranded RNA, which is specific to viruses, and even unmethylated DNA sequences that are characteristic of bacteria.

The book has a model of TLR3, bound to that dsRNA in figure 17 .4.

It shows this large, curved extracellular surface made of leucine -rich repeats.

And that structure gives it flexibility.

When the ligand, the dsRNA, binds,

it forces the TLR dimer to snap together.

And that brings the cytoplasmic domains into close contact.

That structural change is the alert signal.

It kicks off the whole cascade.

Exactly.

And TLR activation is so fundamental that there are drugs designed to enhance it.

Aldaracreme, for instance, acts as an adjuvant to boost the immune response against things like genital warts.

So beyond the receptors, what are the actual mechanisms of the innate response?

Well, it's almost always accompanied by inflammation.

This is where cells and plasma proteins leave the blood vessels and flood into the tissue.

Causing the redness, swelling, and local fever that we're all familiar with.

The function is to concentrate all the defensive agents right at the site of the breach.

But, and this is a big but, inflammation is a double -edged sword.

It's protective.

But if it's not tightly regulated and shut down, it can lead to chronic tissue damage.

Absolutely.

Then you also have direct chemical weapons.

Things like antimicrobial peptides, called defensins, which can directly destroy viruses, bacteria, or fungi.

And the complement system.

A series of soluble proteins in the blood.

When they get activated, they assemble on the pathogen surface.

One outcome, shown back in figure 17 .2b, is that they form a ring that literally perforates the bacterial membrane, causing it to lose.

But what about the threats hiding inside our cells?

The intracellular pathogens.

That's where natural killer cells, or NK cells, come in.

They are non -specific lymphocytes that patrol the body.

Figure 17 .5 shows a pseudo -colored image of a yellow NK cell bound tightly to an orange target cell.

And what they're looking for are compromised cells, infected cells, or certain cancer cells.

Importantly, normal cells display surface molecules that actively inhibit the NK cell.

So it only kills cells that have lost those don't kill me signals.

Precisely.

And the infected cells themselves can even help out by secreting type 1 interferons.

IFN alpha and IFN beta.

Right.

And these proteins bind to neighboring uninfected cells and induce a state of resistance, as we saw in figure 17 .2p.

Have that work?

A couple of ways.

They can inactivate a translation factor called EIF2, which stops viral protein synthesis in its tracks.

And they can induce cellular microRNAs that specifically target and destroy viral RNA genomes.

So the innate system is fast, general, and has all these different mechanisms.

But the most critical piece is the handoff.

The connection to the adaptive system.

They don't just run in parallel.

The facocytic cells and NK cells are what initiate that slower, more specific adaptive response.

They provide the intelligence to make sure only the right cells get called to action.

OK.

So let's level up to adaptive immunity.

This system has three really non -negotiable core properties.

First, there's a lag period.

It takes a few days to get going.

Second, it's exquisitely specific.

It can tell the difference between the measles virus and the mumps virus.

And third, and this is the big one, it generates long -lasting memory.

This is why vaccination is even possible.

And this level of complexity, this memory, is only found in vertebrates.

Right.

And we divide the adaptive response into two interacting arms.

You have humoral immunity, which is mediated by antibodies and targets things outside of cells.

And cell -mediated immunity, mediated by T cells, which goes after infected cells.

The key players for both are the lymphocytes.

Those specialized white blood cells that are constantly circulating between the blood and lymphoid organs.

So let's break them down.

First, B lymphocytes or B cells.

They're the mediators of humoral immunity.

When they get the right signal, they differentiate into these little antibody factories called plasma cells.

And those antibodies then circulate and go after extracellular threats, bacterial walls, toxins, viral coat proteins.

And they work in a couple of ways, which we saw in that overview figure.

They can either neutralize a toxin or virus directly just by binding to it.

Or they can do that opsonization thing where they tag the pathogen for destruction by phagocytes or complement.

Exactly.

Then you have the T lymphocytes or T cells.

The cellular assassins.

The cellular assassins.

They mediate cell -mediated immunity.

And their job is to recognize and directly kill our own cells that have been infected or turned cancerous.

It's the only way to deal with intracellular threats.

And figure 17 .6 lays out their family tree.

Both B and T cells come from hematopoietic stem cells in the bone marrow.

Right.

That stem cell splits into a myeloid progenitor, which makes macrophages, red blood cells, and so on.

And a lymphoid progenitor.

And that lymphoid progenitor is what gives rise to our NK cells, our B cells.

Which mature in the bone marrow.

And our T cells.

Which have to migrate to the thymus to differentiate.

That's why it's called a T cell.

And the fact that we can separate these two branches of immunity is clear from certain diseases, right?

It is.

The book mentions congenital igemaglobulinemia.

It's a condition where people are born without the ability to make antibodies.

But their T cell system works perfectly fine.

Now this is a bit of a turn, but the book spends some time on the plant immune system.

It seems like a detour, but it's conceptually so important.

Plants give us a model of a purely innate immune system.

They don't have mobile immune cells like our white blood cells.

So they have to rely entirely on specialized stationary defenses.

And their challenges are at the entry points.

Wounds or the pores they use for gas exchange.

And their defense comes in waves.

The first wave is PMP -triggered immunity, or PTI.

Just like us, they use transmembrane PRRs to detect general PMPs, like bits of bacterial flagellin or fungal carbohydrates.

And when those receptors bind, it launches a massive internal response.

The book says it leads to the expression of over a thousand genes in the model plant rabidopsis.

It's an immediate sort of scorched earth defense.

They produce antimicrobial enzymes, a flood of reactive oxygen species, and they reinforce the cell wall.

But, as always, the pathogens have adapted.

Plant pathogens are masters of evasion.

They use these specialized secretion systems to inject up to 30 different effector proteins directly into the plant cell to mess with its signaling.

The book gives this great example of a bacterium, Pseudomonas syringae.

It's brilliant, in a sinister way.

It produces a molecular mimic of a plant hormone called jasmineate.

And jasmine normally tells the plant to prepare for an attack by insects.

Exactly.

So the bacterium tricks the plant into launching the completely wrong defense program, which leaves it wide open to the bacterial invasion.

Which means the plant needs a second wave of defense.

Effector -triggered immunity, or ETI.

This is mediated by intracellular proteins called NLRs, which are encoded by specific disease resistance, or are genes.

And you can think of these NLRs as guards that are monitoring the plant's own defense machinery.

That's a great way to put it.

They don't always detect the pathogen itself.

They detect the damage that the pathogen's effectors are doing to crucial host proteins.

Like the classic example, that same bacterium, Pseudomonas syringae, injects a protease that chops up a plant protein called RIN4.

And the plant's NLR protein, RPS2, is essentially watching RIN4 levels.

When it senses that RIN4 has been destroyed, the evidence of tampering, it triggers an explosive immune reaction.

This is all incredibly relevant, because pathogens destroy something like 30 % of global crops.

Which is why researchers are using tools like CRISPR to move these useful R genes from wild resistant plants into our domesticated crops.

Okay, let's get back to the adaptive system and its central mystery.

How does a single antigen lead to this massive production of highly specific antibodies?

This question led to a fundamental concept in immunology.

The clonal selection theory.

Historically, the idea was the instructive model.

It suggested that the antigen somehow molded the antibody into a complementary shape after it showed up.

Right, it implied the immune system was purely reactive.

But that was overturned by the selective proposal.

First by Niels Jern, and then fully expanded by F.

McFarland Burnett.

Into the clonal selection theory in 1957.

And this theory says the body already has this vast pre -existing library of antibodies.

The antigen doesn't instruct, it simply selects the one that already fits.

This is the foundation of everything.

And figure 17 .7 in the book lays out the five core steps of B cell clonal selection.

Step one is commitment.

Every B cell, early in its life, commits to making only one specific kind of antibody.

This happens through irreversible DNA rearrangements, and it happens before it ever sees an antigen.

Step two, pre -existence.

The whole repertoire is already there.

Every B cell displays its unique antibody on its surface, acting as an antigen receptor.

The body is essentially prepared for anything.

Then step three, selection and proliferation.

An antigen comes along and binds to the one B cell in a million that has the matching receptor.

That binding event activates the cell.

And it starts dividing rapidly, forming a clone of identical cells.

Step four is differentiation.

Most of those activated cells differentiate into these short -lived secretory powerhouses called plasma cells.

And figure 17 .9 shows this transformation.

The B cell looks pretty standard, but plasma cell is packed with a huge cytoplasm and an extensive rough endoplasmic reticulum.

It's a cell that has been completely retooled for one job, mass producing and secreting proteins, in this case, antibodies.

And finally, step five, immunologic memory.

A small but critical fraction of the activated cells don't become plasma cells.

They remain as long -lived memory B cells.

These are the cells that can persist for decades.

The book even mentions that survivors of the 1918 flu still have them.

And these memory cells are what allow for a rapid secondary immune response if you ever encounter the same pathogen again.

There's also a critical negative constraint here, right?

Immunologic tolerance.

Yes.

Because this whole process of generating diversity is random, you inevitably create B cells that react against your own body autoantibodies.

The system has to have mechanisms to eliminate or inactivate those cells.

And when that fails, you get autoimmune disease.

Exactly.

The proof for the pre -existence of these cells is really elegant.

It's the column experiment, described in figure 17 .8.

They took spleen cells that had never seen antigen A or antigen B.

They passed them over a column coded with antigen A.

A tiny, tiny fraction of the cells stuck to the column.

When they tested those cells, they only bound to antigen A.

Then they took the vast majority of cells that flowed through and tested them against antigen B.

And again, a tiny fraction of those cells specifically bound to antigen B.

It proved that the specific cells were there waiting before the antigen ever arrived.

It wasn't instructed, it was selected.

And this is exactly why vaccination works.

Jenner's experiment with cowpox worked because it generated memory cells that cross -reacted with smallpox.

Modern vaccines use harmless components like the tetanus toxoid, the toxoid selects the right B cells, builds a clone, and leaves behind memory cells, ready for the real toxin.

And booster shots are just about restimulating that memory population.

Right.

And we should also mention passive immunization.

This is when you give someone antibodies directly, like after a severe injury.

It provides temporary protection, but no memory.

Okay, let's now look at the dark side of this incredible system.

Autoimmune diseases, which the book says affect about 5 % of the population.

This is what happens when that immunologic tolerance fails.

When self -reactive B and T cells somehow escape the body's control mechanisms.

The clinical spectrum is huge.

Let's start with multiple sclerosis, or MS.

This is a chronic inflammatory attack that specifically targets the myelin sheath around nerve axons in the central nervous system.

So this demyelination disrupts the electrical signals in your nerves, leading to severe neurological motor and vision problems.

Right.

Then you have type 1 diabetes, or T1D.

This is the autoimmune destruction of the insulin -secreting beta cells in the pancreas, driven mostly by self -reactive T cells.

The book notes that at diagnosis, patients often still have 10 to 20 % of those cells left.

So a major goal is just to halt the attack.

Then in the thyroid, you can have two opposing problems.

Graves' disease is where autoantibodies constantly stimulate the TSH receptor, leading to hyperthyroidism and overactive thyroid.

TSH is an immune attack that destroys the thyroid cells, leading to hypothyroidism and underactive thyroid.

Rheumatoid arthritis Rios affects about 1 % of people.

It's a progressive destruction of the joints caused by this chronic inflammatory cascade.

And perhaps the most systemic example is systemic lupus arethematosus, or SLE.

This can attack tissues all over the body, heart, kidneys, central nervous system.

SLE patients make autoantibodies against their own nuclear components, like double -stranded DNA.

The book mentions a theory that TLRs, which are supposed to detect microbial DNA, are mistakenly getting activated by the body's own DNA.

There's also a characteristic butterfly rash that often appears on the cheeks in SLE patients, which is described in the human perspective box.

And we should also mention inflammatory bowel diseases, or IBDs, like Crohn's and ulcerative colitis.

This is an inappropriate immune response to the normal, friendly bacteria in our gut.

It's linked to over 200 different genetic loci.

Which brings us to genetics.

There's a strong genetic component, especially with certain alleles of MHC class II polypeptides.

Absolutely.

But it's not the whole story.

In identical twin studies, the concordance rate is only 25 to 75%.

Meaning if one twin has it, the other doesn't always.

So there have to be environmental or epigenetic triggers we don't fully understand yet.

Exactly.

Now this understanding has led to more targeted treatments.

The old way was just blunt force immunosuppressive drugs like prednisone.

But that leaves you vulnerable to all sorts of infections.

The more elegant approach is trying to restore immunological tolerance antigen -specific therapy.

The idea is to make those self -reactive T cells non -responsive or energized.

Another strategy is blocking the destructive chemical signals, the pro -inflammatory cytokines.

Right.

Blocking TNF -alpha with drugs like Humira has been very effective for RA.

But again, it increases the risk of serious infections.

And surprisingly, even in T cell -mediated diseases like MS and RA,

destroying B cells with antibodies like rituxan has proven effective.

It's likely because B cells are also acting as important antigen -presenting cells in those diseases.

And the final category is disrupting immune cell migration,

preventing the activated T cells from getting to the site of damage.

A drug called Tysabri can prevent T cells from crossing the blood -brain barrier in MS patients.

But it carried the risk of a rare viral brain infection.

So for the most severe cases, there's the high -risk, high -reward option.

A hematopoietic stem cell transplant.

It basically resets the entire immune system.

It's very dangerous, but about a third of patients can experience a long -term cure.

Let's shift our focus now entirely onto the T cell.

Like B cells, they operate under clonal selection.

They have a specific T cell receptor, or TCR, and a massive potential repertoire, something like 10 to the 12th T cells with 10 to the 7th different receptors.

But how they recognize an antigen is fundamentally different from a B cell.

Completely different.

The B cell receptor sees the whole intact antigen floating around.

The T cell receptor can only see little fragments of that antigen.

And only when those fragments are held up and displayed by another cell.

An antigen -presenting cell, or APC.

Now any infected cell can be an APC in a way, but there are professionals.

Right, the professional APCs.

Dendritic cells, macrophages, and B cells.

Dendritic cells, or DCs, are the true sentinels.

They guard our peripheral tissues like the skin and airways.

Figure 17 .10 shows these cells.

There's a cup for a cell, which is a macrophage in the liver.

And then the dendritic cell itself, which has this irregular shape with these long searching arms.

They're perfectly designed to sample the environment.

So an immature DC will phagocytose some microbe,

chop it up enzymatically, and then move those little pieces to its cell surface.

Then it migrates to the nearest lymph node to show it is found.

And it presents that evidence to a huge pool of waiting T cells.

There's amazing live cell imaging described in figure 17 .11.

It shows green T cells moving rapidly, scanning the surface of a red dendritic cell.

If there's no match, the contact is breached just a few minutes.

But when a T cell finds the specific antigen its TCR recognizes, that interaction locks in and can last for hours.

The sustained contact is the activation signal.

And once it's activated, the T cell starts that rapid clonal expansion.

This is what makes your lymph nodes swell up when you're sick.

And after the infection is cleared, most of those cells die off, leaving behind that small population of memory T cells.

Right.

And T cells communicate a lot through these chemical messengers called cytokines.

These are small proteins like interferons, interleukins, and tumor necrosis factors.

And we can classify T cells into three major subclasses.

First, the killers, cytotoxic T lymphocytes or CTLs, the CD8 positive cells.

These are the assassins.

Their job is to screen all the other cells in your body for signs of trouble infection, aging, cancer, and to eliminate them by inducing apoptosis.

And they do this in a couple of ways, one of which is releasing perforins and granzymes.

Perforins punch holes in the target cell membrane, and granzymes are enzymes that go through those holes and activate the cell's suicide program.

This is how you deal with viruses hiding inside cells where antibodies can't reach.

Next are the helper T lymphocytes or TH cells, the CD4 positive cells.

These are the communicators, the coordinator.

Yes.

They're absolutely essential for activating other immune cells, especially for getting B cells to mature into those antibody -secreting plasma cells.

Their importance is tragically highlighted by HIV, which specifically targets and destroys TH cells.

AIDS develops when that TH cell count drops below a critical threshold.

And the third class are the regulatory T lymphocytes or T reg cells.

The peacekeepers.

The peacekeepers.

They are inhibitory cells that suppress the activity of other immune cells.

They are vital for maintaining self -tolerance and preventing autoimmunity.

Their development depends on a key transcription factor called FOXP3.

And we can see how the TH cell works in that simplified diagram, figure 17 .12.

It really shows the partnership.

A macrophage eats an antigen and displays a fragment.

A TH cell recognizes that fragment and gets activated.

Then that activated TH cell finds a B cell that is bound to the intact antigen.

And the TH cell then releases a target burst of cytokines right onto the B cell, stimulating it to proliferate and differentiate into plasma cells.

It's a three -way conversation.

Now we get into the really deep molecular weeds, starting with antibody structure.

Antibodies or immunoglobulins are these complex proteins built from two large heavy chains and two smaller light chains,

all held together by disulfide bonds.

And they're five different classes, determined by the heavy chain.

IgM is the first one secreted.

And it's a huge pentamer that's great at activating complement.

Ig is the main one in the secondary response.

It's long -lived and it's the only one that can cross the placenta to give passive immunity to a fetus.

Then you have IgE for allergies and IgA for secretions like tears and breast milk.

And if you look at the classic Y -shaped IgG structure in figure 17 .14, you can see that the chains have a variable portion and a constant portion.

And the antigen binding site is formed by the variable portions of both the heavy and light chains coming together.

The real secret to their specificity is localized in three little stretches within those variable regions, called the hypervariable region.

Figure 17 .14 shows how these regions cluster together at the tips of the Y, forming a pocket.

And that pocket is perfectly complementary to a specific shape on the antigen, which we call the epitope.

You can see this lock and key fit in figure 17 .16.

So the variable region determines what it binds, but the constant region of the heavy chain determines what happens next.

That's the effector function is why IgM activates complement and why IgG can bind to macrophage receptors.

So how does the body generate the insane diversity needed to have an antibody for every possible pathogen?

Through controlled genetic chaos,

DNA rearrangements.

The idea from Trier and Bennett in 1965 was that separate V and C genes must somehow combine.

And Susumu Tonogawa proved it in 1976.

He compared the DNA from an embryonic cell to the DNA from a mature antibody producing cell, as shown in figure 17 .17.

He found that the V and C gene segments were far apart in the embryo, but were physically joined together in the mature cell.

It proved that irreversible DNA rearrangement was happening during B cell development.

The mechanism shown for the light chain in figure 17 .18 is that the germline DNA has multiple different V segments and multiple J or joining segments.

And an enzyme complex called VDJ recombinase randomly picks one V and one J and joins them together, cutting out all the DNA in between.

That combined VJ segment is then spliced to the constant region to make the final messenger RNA.

And the sources of diversity are huge.

You have combinatorial diversity from all the V and J segments.

You have junctional diversity from sloppiness in the joining process.

And the heavy chain is even more complex using three segments, V, D, and J.

The total theoretical diversity is over 200 million different antibody species.

But it doesn't even stop there.

After a B cell is activated, it can actually improve its antibodies affinity.

Through a process called somatic hypermutation, the V regions start mutating at a rate 100 ,000 times higher than the rest of the genome.

B cells that happen to make a better fitting antibody get selected to survive and proliferate.

So the immune response actively gets better over time.

It sharpens its weapons, and it can also do class switching.

As shown in figure 17 .19, a B cell can switch the type of heavy chain it's using, say, from IgM to IgG without changing its antigen specificity.

This is all directed by signals from T helper cells.

Now let's go back to the receptors.

The B cell receptor, or BCR, is that membrane bound antibody.

It recognizes the intact antigen.

The T cell receptor, or TCR on the other hand, is a heterodimer that recognizes a small peptide fragment, but only when it's held by another molecule.

The major histocompatibility complex, or MHC.

This complex was first discovered because it's what governs tissue graft rejection.

The genes are incredibly polymorphic.

There are over 7 ,000 alleles in humans, which is why transplants are so difficult.

But their normal job is antigen presentation.

They act as molecular clipboards, holding those little peptide fragments in a specialized groove for the T cell to see.

T cells don't see the pathogen.

They see a glimpse of the pathogen held in the grip of a self -MHC protein on an APC surface.

This interaction happens at the immunological synapse, as seen in figure 17 .22, where the TCR docks onto the MHC peptide complex.

And we have two main classes.

MHC class I is on almost every cell in the body and displays endogenous or internal antigens.

Think of it as showing what's happening inside the cell.

While MHC class II is only on professional APCs and displays exogenous or external antigens, it shows what the cell has been eating.

And the pathways are different.

For class I, as shown in figure 17 .23a, internal proteins are chopped up by the proteasome.

The peptides are transported into the ER by the TEPI protein and loaded onto a newly made MHC class I molecule.

And this complex then goes to the surface to be inspected by cytotoxic T cells, the CD8 cells.

They are MHC class I restricted.

For class II, shown in figure 17 .23b, the MHC molecule is first blocked by an invariant chain.

It travels to a lysosome that contains fragmented external antigens.

There, the invariant chain is removed and an antigenic peptide is loaded in.

This complex then goes to the surface to be inspected by helper T cells, the CD4 cells.

They are MHC class II restricted.

The discovery of this MHC restriction was a huge breakthrough.

It came from the work of Zinkernagel and Doherty in the 70s.

They were studying a viral brain infection in mice and noticed that susceptibility depended on the mouse's MHC allele.

In their key experiment, described in table 1, the infected mouse fibroblasts of a specific MHC type with the virus.

Then they added CTLs from mice with either the same or different MHC type.

And the result was crystal clear.

The CTLs could only kill the infected cells if they came from a mouse with the exact same MHC allele.

It proved that the T cell has to recognize both the foreign antigen and the self -MHC molecule simultaneously.

Later work by Rosenthal and Unonu showed that the antigen had to be processed first.

They found that blocking lysosomal function with drugs prevented antigen presentation.

The final proof came from structural biology.

In 1987, Don Wiley solved the first 3D structure of an MHC class I molecule.

It showed this deep groove, perfectly sized to hold a peptide.

And in 1996, they solved the structure of the entire TCR -MHC peptide complex.

It showed how the TCR's hypervariable loops fit snugly over the whole thing, with some loops touching the pecpide and others touching the MHC molecule itself.

A single receptor recognizes a composite surface of self and non -self.

Which means T cells have to be rigorously trained before they're released.

This happens in the thymus, a process called thymic selection.

And as figure 17 .25 shows, there are three outcomes.

Negative selection destroys T cells that react too strongly to self -peptides presented on self -MHC.

This prevents autoimmunity.

Then death by neglect kills off T cells that can't recognize self -MHC at all.

They're useless.

And finally, positive selection allows the survival of T cells that have a weak affinity for self -MHC complexes.

Less than 5 % of T cells make it through this process.

And even after all that, there's another safety check.

To get activated, a T cell needs two separate signals.

As shown in figure 17 .26a, signal 1 is the specific TCR binding to the MHC peptide complex.

But that's not enough.

You also need signal 2, a costimulatory signal.

This is usually the interaction between the CD28 protein on the T cell and a B7 protein on the APC, which only appears after the APC has ingested a pathogen.

What happens if you only get signal 1?

The T cell becomes energized, or non -responsive, or it just dies.

This is the crucial safeguard that prevents T cells from attacking normal, healthy body cells.

And even after activation, there's a break.

A protein called CTLA -4 comes to the surface, and when it vines to B7, it sends an inhibitory signal.

It's essential for shutting down the response.

Mice that lack CTLA -4 die from massive T cell overproliferation.

All of this incredibly detailed knowledge is now being used to engineer cancer therapies.

Adoptive T cell therapy.

The idea is we can enhance the immune system's natural ability to destroy malignant cells.

We take T cells from a patient, engineer them to express a new receptor, grow them to huge numbers, and then put them back in.

One version is TCR T cell therapy, where you give the cells a new transgenic TCR.

The problem here is that it still requires the tumor cell to express MHC, and tumors often evolve to lose MHC expression to hide from the immune system.

There's also a huge risk of off -target toxicity.

The book cites a trial where the engineered TCR for a melanoma antigen accidentally recognizes similar protein in the brain and heart with fatal results.

The more recent excitement is around CAR -TAR T cell therapy, using a chimeric antigen receptor.

The CHI CAR, shown in figure 17 .27, is a brilliant piece of engineering.

It combines the antigen recognition part of an antibody with the signaling machinery of TCR.

It completely bypasses the need for MHC presentation.

It can recognize proteins directly on the tumor cell surface.

And it's had incredible success against B cell leukemias by targeting an antigen called CD19.

Response rates up to 90 % in patients who had failed chemotherapy.

But it has so far been unsuccessful against solid tumors, and it carries its own risks, like severe cytokine release.

The future is about making these therapies safer and more broadly applicable.

Finally, let's look under the hood at the signal transduction pathways that make all this happen.

Lymphocyte activation uses a lot of the same components as hormone signaling, with one key difference.

The lymphocyte receptors themselves don't have any intrinsic enzyme activity.

So when the receptor binds its ligand, it has to recruit cytoplasmic tyrosine kinases, like from the Sandor Sheen Tech families.

Right.

And those kinases then kick off all the familiar pathways.

Phospholipase C, the RasMap kinase cascade, and the PI3K pathway.

All of this converges on activating transcription factors, like NF -kappa -B and NFA, which turn on dozens of genes needed for the immune response.

And then for cytokines, there's a more direct pathway called the JAK -STAT pathway.

It's unusual because it doesn't use second messengers.

The cytokine receptor binding activates associated kinases called JAKs.

And the JAKs directly phosphorylate transcription factors called STATs.

The phosphorylated STATs then form a dimer, go straight to the nucleus, and bind specific DNA sequences to turn on genes.

And the specificity comes from which JAKs and STATs are used.

So IL -4 in a B cell will activate STAT -6 for class switching, while interferon activates STAT -1 for viral resistance.

We have covered an immense amount of ground from the failure of the immune system in the case of Ebola to the genetic acrobatics needed to generate diversity.

I think the key takeaways are really about this collaboration between the fast, general, innate system and the slow, specific adaptive system, the molecular marvels of DNA rearrangement and somatic hypermutation.

And crucially,

the constraints on T cell function,

MHC restriction, chemics selection, and that delicate balance of activation and inhibition that's required for self -tolerance.

That two -signal requirement really is our ultimate insurance policy.

It is, and it makes you wonder, given how tightly the system is engineered for stability, what subtle shifts environmental, maybe epigenetic, could be enough to push a memory T cell that survived selection decades ago to suddenly overcome that CTLA -4 break and wage war on the body's own tissues?

How fine is that line between stability and immunological breakdown?

A question that defines a huge amount of modern immunology research.

It does.

Thank you for engaging in this deep dive into the immune response.

We really appreciate you joining us for this incredibly detailed look into the chapter.

We'll catch you next time.